查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1477495

真性紅血球增多症藥物市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型、最終用戶、地區和競爭細分，2019-2029F

Polycythemia Vera Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By End User, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 187 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年全球真性紅血球增多症真性紅血球增多症市場價值為 11.1 億美元，預計在預測期內將穩定成長，到 2029 年複合年成長率為 5.25%。其特徵是骨髓中的紅血球。這種情況可能導致嚴重的併發症，如凝血、中風和心臟病。真性紅血球增多症的管理和治療涉及多種旨在控制血球生成和降低併發症風險的藥物。隨著對真性紅血球增多症了解的加深和新治療選擇的出現，真性紅血球增多症藥物的全球市場出現了顯著成長。全球真性紅血球增多症藥物市場的推動因素包括該疾病盛行率的不斷上升、醫學研究的進步以及對更有效治療方案不斷成長的需求。隨著人口老化和與PV相關的風險因素的增加，製藥公司正在大力投資研發，將創新療法推向市場。多家製藥公司正積極致力於真性紅血球增多症藥物的開發和商業化。全球市場的一些主要參與者包括因塞特公司、諾華公司、百時美施貴寶公司等。這些公司專注於傳統和新穎的治療方法來解決真性紅斑狼瘡的複雜性。

市場概況
預測期 2025-2029
2023 年市場規模 11.1億美元
2029 年市場規模 15.1億美元
2024-2029 年複合年成長率 5.25%
成長最快的細分市場 達沙替尼
最大的市場 北美洲

主要市場促進因素

真性紅血球增多症盛行率的增加正在推動全球真性紅血球增多症藥物市場的發展

醫療支出的增加正在推動全球真性紅血球增多症藥物市場

主要市場挑戰

治療費用高

主要市場趨勢

技術進步

細分市場洞察

類型洞察

最終使用者見解

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：全球真性紅血球增多症藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型（Dasatinib、Idelalisib、Givinostat、M-009、其他）
    • 按最終使用者（醫院和診所、門診護理中心、其他）
    • 按地區
    • 按公司分類 (2023)
  • 市場地圖
    • 按類型
    • 按最終用戶
    • 按地區

第 5 章：亞太地區真性紅血球增多症藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第 6 章：歐洲真性紅血球增多症藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 7 章：北美真性紅血球增多症藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 8 章：南美洲真性紅血球增多症藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 9 章：中東和非洲真性紅血球增多症藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 10 章：市場動態

  • 促進要素
  • 挑戰

第 11 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 12 章：全球真性紅血球增多症藥物市場：SWOT 分析

第 13 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • Teva Pharmaceutical Industries Ltd.
  • ANP Technologies Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences
  • Karus Therapeutics Limited
  • miRagen Therapeutics Inc.
  • Nerviano Medical Sciences Srl
  • Novartis AG
  • PharmaEssentia Corporation

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 23945

Global Polycythemia Vera Drug Market was valued at USD 1.11 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2029. Polycythemia Vera (PV) is a rare, chronic blood cancer characterized by the overproduction of red blood cells in the bone marrow. This condition can lead to serious complications such as blood clotting, stroke, and heart attack. The management and treatment of Polycythemia Vera involve a variety of drugs aimed at controlling blood cell production and reducing the risk of complications. The global market for Polycythemia Vera drugs has witnessed significant growth as the understanding of the disease improves and novel therapeutic options emerge. The global Polycythemia Vera drug market is driven by an increasing prevalence of the disease, advancements in medical research, and a growing demand for more effective treatment options. With an aging population and the rise in risk factors associated with PV, pharmaceutical companies are investing heavily in research and development to bring innovative therapies to the market. Several pharmaceutical companies are actively contributing to the development and commercialization of drugs for Polycythemia Vera. Some of the key players in the global market include Incyte Corporation, Novartis AG, Bristol Myers Squibb Company, and others. These companies are focusing on both traditional and novel therapeutic approaches to address the complex nature of PV.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 1.11 Billion
Market Size 2029USD 1.51 Billion
CAGR 2024-20295.25%
Fastest Growing SegmentDasatinib
Largest MarketNorth America

Key Market Drivers

Increasing Prevalence of Polycythemia Vera is Driving the Global Polycythemia Vera Drug Market

Polycythemia Vera (PV) is a rare blood disorder characterized by the overproduction of red blood cells in the bone marrow. While it remains an uncommon condition, the global prevalence of Polycythemia Vera has been on the rise, propelling the demand for effective treatments. This surge in cases has led to a significant expansion in the Global Polycythemia Vera Drug Market, as pharmaceutical companies strive to develop innovative therapies to address the specific needs of patients with this disorder. Recent years have witnessed a notable uptick in the prevalence of Polycythemia Vera worldwide. The exact reasons for this increase are multifaceted, with factors such as aging populations, improved diagnostic capabilities, and heightened awareness contributing to the rise in reported cases. The prevalence is particularly higher in older individuals, with most cases diagnosed in individuals over the age of 60.

As the prevalence of Polycythemia Vera continues to climb, there is a growing recognition of the substantial burden it places on affected individuals and healthcare systems. Patients with PV often face an increased risk of cardiovascular events, thrombosis, and transformation to more aggressive forms of myeloproliferative neoplasms. This necessitates a comprehensive approach to managing the condition, including the development of targeted and efficient therapeutic interventions. The rise in the number of Polycythemia Vera cases has spurred pharmaceutical companies to invest in research and development to bring forth novel drugs for managing and treating the disorder. The Global Polycythemia Vera Drug Market has witnessed a surge in product launches, clinical trials, and collaborations aimed at advancing therapeutic options. Several innovative drugs and therapies have emerged as promising candidates for the treatment of Polycythemia Vera. JAK inhibitors, such as ruxolitinib, have shown efficacy in reducing the risk of thrombosis and improving symptoms associated with PV. Other targeted therapies, including interferon-alpha and pegylated interferon, are also being explored for their potential in managing this rare blood disorder.

Increasing Healthcare Expenditure is Driving the Global Polycythemia Vera Drug Market

The escalating healthcare expenditure worldwide has created a conducive environment for pharmaceutical companies to invest in research and development, leading to the discovery and introduction of novel drugs for treating Polycythemia Vera. Governments and private institutions alike are allocating substantial resources to healthcare, recognizing the need for cutting-edge solutions to address complex medical conditions. Increased funding has enabled pharmaceutical companies to invest in extensive research and development efforts, striving to bring about breakthroughs in Polycythemia Vera treatment. This has led to the discovery of targeted therapies and more effective drugs with fewer side effects. The rise in healthcare expenditure has paved the way for the development of innovative drug formulations, such as long-acting medications and combination therapies. These advancements aim to enhance patient adherence to treatment regimens and improve overall therapeutic outcomes.

Higher healthcare spending allows for improved patient access to advanced and expensive therapies. This, in turn, has increased the adoption of novel drugs for Polycythemia Vera, thereby driving market growth. Increased healthcare spending contributes to enhanced awareness campaigns and diagnostic capabilities. As a result, more cases of Polycythemia Vera are being diagnosed at earlier stages, leading to timely and effective interventions.

Key Market Challenges

High Treatment Costs

The development of novel and effective drugs for Polycythemia Vera involves extensive research and clinical trials. The costs associated with these processes, including testing, regulatory approvals, and ensuring safety and efficacy, are significant. Pharmaceutical companies aim to recover these expenses, leading to higher prices for the end-users. The rarity of Polycythemia Vera compared to more prevalent diseases means that fewer pharmaceutical companies invest in developing treatments for this condition. Limited competition can result in higher prices as companies hold a stronger market position without the pressure to lower costs. The complexity of Polycythemia Vera and the need for targeted therapies contribute to the high cost of treatment. Medications that specifically target the underlying causes of PV often require advanced technologies and specialized manufacturing processes, adding to production expenses. Patients with Polycythemia Vera require continuous monitoring through regular blood tests and medical consultations. The ongoing nature of disease management adds to the overall cost of treatment, making it a long-term financial commitment for both individuals and healthcare systems.

Key Market Trends

Technological Advancements

The pharmaceutical industry has witnessed a surge in technological innovations that significantly impact the drug discovery process. Advances in genomics, proteomics, and high-throughput screening have revolutionized the identification and validation of drug targets. Researchers can now delve deeper into the molecular mechanisms underlying PV, facilitating the discovery of novel therapeutic targets. The era of one-size-fits-all medicine is gradually giving way to precision medicine, wherein treatments are tailored to individual patients based on their genetic makeup, lifestyle, and other factors. In the context of PV, this approach allows for more targeted and effective interventions. Technological tools like next-generation sequencing enable healthcare professionals to analyze a patient's genetic profile, identifying specific mutations or markers associated with PV. This information can guide the development of personalized therapies with higher efficacy and fewer side effects.

In addition to innovations in drug discovery, advancements in drug delivery systems contribute to the improved effectiveness of Polycythemia Vera treatments. Nanotechnology, for instance, allows for the development of nanocarriers that can enhance drug bioavailability and target specific cells or tissues. This can result in reduced side effects and improved patient compliance, making the treatment of PV more manageable for individuals with this condition. The integration of digital health solutions into the management of Polycythemia Vera has further enhanced patient care. Mobile applications, wearable devices, and telemedicine platforms enable real-time monitoring of patients' vital signs, medication adherence, and overall health. These technologies empower both patients and healthcare providers, fostering a more proactive and collaborative approach to PV management. Continuous monitoring and instant data feedback enable timely interventions, potentially preventing complications and improving treatment outcomes.

Technological advancements have facilitated collaborative research efforts on a global scale. Researchers and pharmaceutical companies can now share data more efficiently, leading to a more comprehensive understanding of Polycythemia Vera and its underlying mechanisms. Big data analytics play a crucial role in processing vast amounts of information, identifying patterns, and extracting valuable insights. This data-driven approach accelerates the drug development process, potentially shortening the time from discovery to market availability. s.

Segmental Insights

Type Insights

Based on the category of type, Dasatinib emerged as the dominant segment in the global market for Polycythemia Vera Drug in 2023. Dasatinib is a tyrosine kinase inhibitor that was initially developed for the treatment of chronic myeloid leukemia (CML). However, its efficacy in targeting abnormal cell growth and proliferation made it a promising candidate for other hematological disorders, including PV. Clinical trials and real-world evidence have demonstrated Dasatinib's effectiveness in managing PV symptoms and reducing the risk of complications associated with the disease. The drug works by inhibiting specific enzymes and signaling pathways responsible for the abnormal production of blood cells.

End User Insights

The Hospitals & Clinics segment is projected to experience rapid growth during the forecast period. Hospitals and clinics provide a comprehensive approach to patient care, offering a wide range of diagnostic, therapeutic, and supportive services under one roof. This is crucial for the effective management of Polycythemia Vera, which often requires a multidisciplinary approach involving hematologists, oncologists, and other specialists. The accurate diagnosis of Polycythemia Vera is crucial for appropriate treatment. Hospitals and clinics typically house advanced diagnostic facilities, including specialized laboratories and imaging services, ensuring prompt and precise identification of the disorder. Polycythemia Vera necessitates specialized medical expertise for its management. Hospitals often have a team of experienced healthcare professionals, including hematologists and oncologists, who can provide specialized care and personalized treatment plans tailored to the individual needs of PV patients.

Regional Insights

North America emerged as the dominant region in the global Polycythemia Vera Drug market in 2023, holding the largest market share in terms of value. The dominance of North America in the global Polycythemia Vera drug market can be attributed to several factors. One crucial element is the region's advanced healthcare infrastructure, which fosters research and development in the pharmaceutical industry. The United States, in particular, boasts a robust network of research institutions, pharmaceutical companies, and healthcare facilities, contributing significantly to the growth of the PV drug market. Additionally, North America has witnessed a surge in awareness about rare diseases, including Polycythemia Vera. Increased awareness has led to early diagnosis and a growing demand for effective treatments, driving pharmaceutical companies to invest in the development of innovative drugs.

Key Market Players

Teva Pharmaceutical Industries Ltd.

ANP Technologies Inc.

Bristol-Myers Squibb Company

F. Hoffmann-La Roche Ltd.

Gilead Sciences

Karus Therapeutics Limited

miRagen Therapeutics Inc.

Nerviano Medical Sciences S.r.l.

Novartis AG

PharmaEssentia Corporation

Report Scope:

In this report, the Global Polycythemia Vera Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Polycythemia Vera Drug Market, By Type:

    Dasatinib Idelalisib Givinostat M-009 Others

Polycythemia Vera Drug Market, By End User:

    Hospitals& Clinics Ambulatory Care Centers Others

Polycythemia Vera Drug Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia-Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Polycythemia Vera Drug Market.

Available Customizations:

Global Polycythemia Vera Drug market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Polycythemia Vera Drug Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Type (Dasatinib, Idelalisib, Givinostat, M-009, Others)
    • 4.2.2. By End User (Hospitals& Clinics, Ambulatory Care Centers, Others)
    • 4.2.3. By Region
    • 4.2.4. By Company (2023)
  • 4.3. Market Map
    • 4.3.1. By Type
    • 4.3.2. By End User
    • 4.3.3. By Region

5. Asia Pacific Polycythemia Vera Drug Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type
    • 5.2.2. By End User
    • 5.2.3. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Polycythemia Vera Drug Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Type
        • 5.3.1.2.2. By End User
    • 5.3.2. India Polycythemia Vera Drug Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Type
        • 5.3.2.2.2. By End User
    • 5.3.3. Australia Polycythemia Vera Drug Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Type
        • 5.3.3.2.2. By End User
    • 5.3.4. Japan Polycythemia Vera Drug Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Type
        • 5.3.4.2.2. By End User
    • 5.3.5. South Korea Polycythemia Vera Drug Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Type
        • 5.3.5.2.2. By End User

6. Europe Polycythemia Vera Drug Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Polycythemia Vera Drug Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Germany Polycythemia Vera Drug Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Spain Polycythemia Vera Drug Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By End User
    • 6.3.4. Italy Polycythemia Vera Drug Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Type
        • 6.3.4.2.2. By End User
    • 6.3.5. United Kingdom Polycythemia Vera Drug Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Type
        • 6.3.5.2.2. By End User

7. North America Polycythemia Vera Drug Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Polycythemia Vera Drug Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By End User
    • 7.3.2. Mexico Polycythemia Vera Drug Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By End User
    • 7.3.3. Canada Polycythemia Vera Drug Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By End User

8. South America Polycythemia Vera Drug Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Polycythemia Vera Drug Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By End User
    • 8.3.2. Argentina Polycythemia Vera Drug Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Colombia Polycythemia Vera Drug Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By End User

9. Middle East and Africa Polycythemia Vera Drug Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Polycythemia Vera Drug Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By End User
    • 9.3.2. Saudi Arabia Polycythemia Vera Drug Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By End User
    • 9.3.3. UAE Polycythemia Vera Drug Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By End User

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Polycythemia Vera Drug Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Teva Pharmaceutical Industries Ltd.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Product & Services
    • 14.1.4. Financials (In case of listed)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. ANP Technologies Inc.
  • 14.3. Bristol-Myers Squibb Company
  • 14.4. F. Hoffmann-La Roche Ltd.
  • 14.5. Gilead Sciences
  • 14.6. Karus Therapeutics Limited
  • 14.7. miRagen Therapeutics Inc.
  • 14.8. Nerviano Medical Sciences S.r.l.
  • 14.9. Novartis AG
  • 14.10. PharmaEssentia Corporation

15. Strategic Recommendations

16. About Us & Disclaimer